First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM study | Synapse
March 28, 2026
First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM study
Key Points
To analyze the effects of first-line immunochemotherapy on muscle volume in patients with long-term remission from indolent lymphoma.
Conducted a post hoc analysis of the GALLIUM study data.
Included 472 patients in long-term remission.
Assessed muscle volume changes using imaging techniques.
No significant changes in muscle volume were observed after treatment.
Muscle health remained stable despite immunochemotherapy.
Findings highlight the physical health stability of patients in remission.
Abstract
The GALLIUM trial: ClinicalTrials. gov number, NCT01332968.